Clinical Trial Update: Letrozole in the Treatment of Advanced or Recurrent Hormone Receptor Positive Endometrial Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating letrozole for advanced or recurrent hormone receptor-positive endometrial cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• FEMARA (letrozole)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Endometrial Cancer | Phase 2 | Status: COMPLETED